Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_provenance.
- befree-20150227 importedOn "2015-02-27" NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_provenance.
- NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_assertion wasGeneratedBy ECO_0000203 NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_provenance.
- NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_assertion wasDerivedFrom befree-20150227 NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_provenance.
- NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_assertion SIO_000772 3504435 NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_provenance.
- NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_assertion evidence source_evidence_literature NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_provenance.
- NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_assertion description "[The distribution of the treatment-related MDS cases was different than 'de novo' MDS with a high percentage of RAEB-T, and with the treatment related AMLs, there were a higher percentage of patients with FAB M6 (erythroleukemia), and no cases of FAB M3 (hypergranular promyelocytic).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781313.RA8Kx9Vtb5RfEfdLDZLw8-pLDRiHyuT2A5aP3G9wtQ7Kw130_provenance.